Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide

• US 6,894,024 B2
• Filed: 10/22/2001
• Issued: 05/17/2005
• Est. Priority Date: 10/20/2000
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Coolidge, Thomas R., Ehlers, Mario
• Primary Examiner(s): MELLER, MICHAEL V
• Application Number:
  US09/982,978
• Publication Number:
  US 20020146405A1
• Time in Patent Office: 1,303 Days
• Field of Search: 514/2
• US Class Current: 514/11.7
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

Claims

1. A method of treating a patient suffering from diabetic cardiomyopathy, comprising administering an effective amount of compound selected from the group consisting of Glucagon-Like Peptide-1 (GLP-1), GLP-1 analogs, and GLP-1-like peptides, to a patient suffering from diabetic cardiomyopathy.

2. The method of claim 1, wherein the administration is continuous.

3. The method of claim 1, wherein the administration is parenteral.

4. The method of claim 1, wherein said effective amount of said compound is effective to cause a reduction in the plasma or heart norepinepherine level.

5. The method of claim 3, wherein said compound is administered in a dose of from about 0.1-10 pmol/kg/min.

6. The method of claim 1 wherein said compound is administered subcutaneously in a dose of about 0.5-50 pmol/kg/min.

7. The method of claim 1 wherein said compound is administered in a dose of up to 10.0 nmol/kg.

8. The method of claim 1, wherein said compound is administered intravenously in a dose of about 0.1-10 pmol/kg/min.

9. The method of claim 1, wherein said compound is selected from the group consisting of GLP-1(1-37), GLP-1(1-36)NH₂, GLP-1(7-37), and GLP-1(7-36)NH2.